|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 评估SCG142自体T细胞注射液治疗复发或转移性HPV16或HPV52相关恶性肿瘤的安全性和初步疗效的开放、单臂、多中心的I期研究
[Translation] An open, single-arm, multicenter phase I study to evaluate the safety and preliminary efficacy of SCG142 autologous T cell injection in the treatment of recurrent or metastatic HPV16 or HPV52-related malignancies
主要研究目的是评估SCG142治疗HPV16或HPV52相关恶性肿瘤的安全性、耐受性。次要研究目的是评估SCG142治疗HPV16或HPV52相关恶性肿瘤的初步临床疗效及SCG142静脉输注前、后药代动力学特征。
[Translation] The primary study objective is to evaluate the safety and tolerability of SCG142 in the treatment of HPV16 or HPV52-related malignancies. The secondary study objective is to evaluate the preliminary clinical efficacy of SCG142 in the treatment of HPV16 or HPV52-related malignancies and the pharmacokinetic characteristics of SCG142 before and after intravenous infusion.
100 Clinical Results associated with Xinghande Biomedical (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Xinghande Biomedical (Shanghai) Co., Ltd.
100 Deals associated with Xinghande Biomedical (Shanghai) Co., Ltd.
100 Translational Medicine associated with Xinghande Biomedical (Shanghai) Co., Ltd.